Oral DHA treatment increased the ratio of LC3 II/I (+65.98% AD vs. AD-DHA, p < 0.01; Figures 5D,E) and the blocked degradation of SQSTM/p62 (p < 0.01; Figures 5D,E) was significantly reverted in DHA-treated AD group, compared with the DMSO-treated AD group. This evidence concerns the gene SQSTM1 and Alzheimer disease.